The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders

Show simple item record

dc.contributor.author Mari, Jair de Jesus [UNIFESP]
dc.contributor.author Lima, Mauricio Silva de [UNIFESP]
dc.contributor.author Costa, Anna Maria Niccolai [UNIFESP]
dc.contributor.author Alexandrino, Neusa
dc.contributor.author Rodrigues-Filho, Salomao
dc.contributor.author Oliveira, Irismar Reis de
dc.contributor.author Tollefson, Gary D.
dc.date.accessioned 2018-06-15T17:17:33Z
dc.date.available 2018-06-15T17:17:33Z
dc.date.issued 2004-12-01
dc.identifier http://dx.doi.org/10.1007/s00406-004-0514-1
dc.identifier.citation European Archives Of Psychiatry And Clinical Neuroscience. Darmstadt: Dr Dietrich Steinkopff Verlag, v. 254, n. 6, p. 356-361, 2004.
dc.identifier.issn 0940-1334
dc.identifier.uri http://repositorio.unifesp.br/11600/43579
dc.description.abstract Aims of the study To assess the impact of olanzapine versus conventional neuroleptic therapy among subjects with schizophrenia on ratings of tardive dyskinesia (TD). Method The naturalistic study was conducted in three psychiatric hospitals in Brazil. Patients had a diagnosis of schizophrenia and related disorders (DSMIV) and with a BPRS score > 24. Patients were evaluated by means of the PANSS scale for symptomatology (Kay et al. 1986), the Clinical Global Impression, The UKU side effect rating scale (Lingjaerde et al. 1987), and the Tardive Dyskinesia AIMS scale (Guy et al. 1976). Patients were seen by the treating physician routinely while hospitalized and then monthly on an out-patient basis. All scale assessments were repeated after 9 months of discharge. Result The sample was comprised of 190 patients (99 in the olanzapine and 91 in the standard treatment), with a completion rate of 88.2 % for olanzapine and 84.9 % for the conventional treatment (p = 0.385, n. s.). The mean change from baseline in the PANSS total score favored olanzapine regarding negative symptoms (2.3, 95% C.I. 0.6-4.1, p<0.001); and general psychopathology (4.0, 95% C.I. 0.8-7.2, p<0.02) factors. TD was defined by applying Morgenstern & Glazer (1993) and Schooler & Kane (1982) criteria, on the basis of the AIMS scale. Both results favored olanzapine at the end of the follow-up (Morgenstern & Glazer: 25.6 % versus 56.3 %; Schooler & Kane: 16.3 % versus 45.2 %). At the end of the follow-up, by using the overall rating of the AIMS scale, the presence of TD was 2.3 % for olanzapine (2/87), and 16.7 % (12/72) for the conventional treatment. Conclusions The results of this open label naturalistic trial showed that olanzapine had an impact on negative symptoms, decreased general psychopathology and reduced the risk of tardive dyskinesia. en
dc.format.extent 356-361
dc.language.iso eng
dc.publisher Dr Dietrich Steinkopff Verlag
dc.relation.ispartof European Archives Of Psychiatry And Clinical Neuroscience
dc.rights Acesso aberto
dc.subject schizophrenia en
dc.subject Tardive dyskinesia en
dc.subject randomized controlled trial en
dc.subject olanzapine en
dc.subject typical antipsychotic en
dc.title The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders en
dc.type Artigo
dc.contributor.institution Universidade Federal de São Paulo (UNIFESP)
dc.contributor.institution Fed Univ Pelotas
dc.contributor.institution Catholic Univ Pelotas
dc.contributor.institution Hosp Anna Rech
dc.contributor.institution Pax Clin Psiquiatrica Goiania
dc.contributor.institution Universidade Federal da Bahia (UFBA)
dc.description.affiliation Univ Fed Sao Paulo, Dept Psiquiatria, BR-04023900 Sao Paulo, Brazil
dc.description.affiliation Fed Univ Pelotas, Dept Psychiat, Eli Lilly, Brazil
dc.description.affiliation Catholic Univ Pelotas, Eli Lilly, Brazil
dc.description.affiliation Hosp Anna Rech, Rio Grande Do Sul, Brazil
dc.description.affiliation Pax Clin Psiquiatrica Goiania, Goias, Brazil
dc.description.affiliation Univ Fed Bahia, Dept Neuropsychiat & Neurol, BR-41170290 Salvador, BA, Brazil
dc.description.affiliationUnifesp Univ Fed Sao Paulo, Dept Psiquiatria, BR-04023900 Sao Paulo, Brazil
dc.identifier.doi 10.1007/s00406-004-0514-1
dc.description.source Web of Science
dc.identifier.wos WOS:000226092900002



File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search


Browse

Statistics

My Account